COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.
Vaccines (Basel)
; 9(3)2021 Mar 04.
Article
de En
| MEDLINE
| ID: mdl-33806646
ABSTRACT
Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Langue:
En
Journal:
Vaccines (Basel)
Année:
2021
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique